HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Wants Remote Regulatory Assessment Authority For Cosmetics – FY 2023 Budget Justification

Executive Summary

After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.

You may also be interested in...



'Could Put Us Out Of Business’: US State Bill Pileup Has Small Beauty Set On Federal Preemption

The cosmetics industry has an “optics” problem, and that is creating other issues, namely a growing body of state legislation to address perceived gaps in federal regulatory oversight.

US FDA Packages Suggestions To Amend DSHEA In Fiscal Year 2023 Budget Request

Biden administration’s FY2023 budget request for FDA includes $1.23bn for food programs, which include regulation of supplement manufacturing and marketing. The funding, an increase of more than $128,000 from FDA’s current food programs budget, would be split between $419,932 for CFSAN and $800,261 for related field work by ORA.

Biden Requests US FDA Budget Surge: Pandemic Preparedness Money Would Increase Funding 36%

President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel